Denali Therapeutics Inc.

Symbol: DNLI

NASDAQ

20.86

USD

Market price today

  • -20.3241

    P/E Ratio

  • -0.2177

    PEG Ratio

  • 2.88B

    MRK Cap

  • 0.00%

    DIV Yield

Denali Therapeutics Inc. (DNLI) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

1.60%

Operating Profit Margin

20.06%

Net Profit Margin

14.22%

Return on Assets

-0.09%

Return on Equity

-0.11%

Return on Capital Employed

-0.13%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Ryan J. Watts Ph.D.
Full-time employees:445
City:South San Francisco
Address:161 Oyster Point Boulevard
IPO:2017-12-08
CIK:0001714899

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

General Outlook

When we look at how much money they make before expenses, they keep 1.596% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 20.056%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 14.218%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.087% return, is a testament to Denali Therapeutics Inc.'s adeptness in optimizing resource deployment. Denali Therapeutics Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.115%. Furthermore, the proficiency of Denali Therapeutics Inc. in capital utilization is underscored by a remarkable -0.129% return on capital employed.

Stock Prices

Denali Therapeutics Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $16.72, while its low point bottomed out at $15.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Denali Therapeutics Inc.'s stock market.

Liquidity Ratios

Analyzing DNLI liquidity ratios reveals its financial health of the firm. The current ratio of 1178.92% gauges short-term asset coverage for liabilities. The quick ratio (1134.47%) assesses immediate liquidity, while the cash ratio (73.35%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1178.92%
Quick Ratio1134.47%
Cash Ratio73.35%

Profitability Ratios

DNLI profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 1421.48% underscores its earnings before tax deductions. The effective tax rate stands at 1.64%, revealing its tax efficiency. The net income per EBT, 100.02%, and the EBT per EBIT, 70.88%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 2005.58%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin1421.48%
Effective Tax Rate1.64%
Net Income per EBT100.02%
EBT per EBIT70.88%
EBIT per Revenue2005.58%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 11.79, it details the span from stock purchase to revenue. The 11 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding1134
Days of Payables Outstanding752
Cash Conversion Cycle-752
Payables Turnover0.49
Fixed Asset Turnover-0.13
Asset Turnover-0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -2.76, and free cash flow per share, -2.85, depict cash generation on a per-share basis. The cash per share value, 6.27, showcases liquidity position. Lastly, the operating cash flow sales ratio, 42.76, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-2.76
Free Cash Flow per Share-2.85
Cash per Share6.27
Operating Cash Flow Sales Ratio42.76
Free Cash Flow to Operating Cash Flow Ratio1.03
Cash Flow Coverage Ratio-8.17
Short Term Coverage Ratio-54.95
Capital Expenditure Coverage Ratio-33.55
Dividend Paid and Capex Coverage Ratio-33.55

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 3.20%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.03, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.87%, and total debt to capitalization, 3.36%, ratios shed light on its capital structure. An interest coverage of -9.18 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio3.20%
Debt Equity Ratio0.03
Long Term Debt to Capitalization2.87%
Total Debt to Capitalization3.36%
Interest Coverage-9.18
Cash Flow to Debt Ratio-8.17
Company Equity Multiplier1.09

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.41, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.06, reflects the portion of profit attributed to each share. The book value per share, 7.50, represents the net asset value distributed per share, while the tangible book value per share, 7.50, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.41
Net Income Per Share-1.06
Book Value Per Share7.50
Tangible Book Value Per Share7.50
Shareholders Equity Per Share7.50
Interest Debt Per Share0.38
Capex Per Share-0.09

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 204.74%, indicates top-line expansion, while the gross profit growth, 209.38%, reveals profitability trends. EBIT growth, 42.27%, and operating income growth, 42.27%, offer insights into operational profitability progression. The net income growth, 55.45%, showcases bottom-line expansion, and the EPS growth, 59.23%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth204.74%
Gross Profit Growth209.38%
EBIT Growth42.27%
Operating Income Growth42.27%
Net Income Growth55.45%
EPS Growth59.23%
EPS Diluted Growth59.23%
Weighted Average Shares Growth9.43%
Weighted Average Shares Diluted Growth9.43%
Operating Cash Flow Growth-46.29%
Free Cash Flow Growth-41.28%
5-Year Revenue Growth per Share72.55%
3-Year Revenue Growth per Share-21.88%
10-Year Operating CF Growth per Share47.95%
5-Year Operating CF Growth per Share-581.63%
3-Year Operating CF Growth per Share-168.24%
10-Year Net Income Growth per Share81.07%
5-Year Net Income Growth per Share-170.19%
3-Year Net Income Growth per Share-261.95%
10-Year Shareholders Equity Growth per Share244.32%
5-Year Shareholders Equity Growth per Share27.11%
3-Year Shareholders Equity Growth per Share-28.92%
Receivables Growth-46.00%
Inventory Growth100.00%
Asset Growth-20.98%
Book Value per Share Growth-9.63%
Debt Growth-13.44%
R&D Expense Growth18.16%
SGA Expenses Growth-4.25%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,873,114,449.62, captures the company's total value, considering both debt and equity. Income quality, 2.47, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.31, gauges operational efficiency, while the research and development to revenue, 128.24%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value2,873,114,449.62
Income Quality2.47
Sales General and Administrative to Revenue0.31
Research and Development to Revenue128.24%
Capex to Operating Cash Flow3.61%
Capex to Revenue-3.91%
Capex to Depreciation-77.36%
Stock-Based Compensation to Revenue32.71%
Graham Number13.36
Return on Tangible Assets-12.59%
Graham Net Net6.65
Working Capital986,155,000
Tangible Asset Value1,030,954,000
Net Current Asset Value941,174,000
Average Receivables3,850,000
Average Payables6,136,500
Average Inventory-2,499,999.5
Days Sales Outstanding3
Days Payables Outstanding207
ROIC-18.16%
ROE-0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.92, and the price to book ratio, 1.92, reflect the market's valuation relative to the company's book value. The price to sales ratio, -275.69, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -6.26, and price to operating cash flows, -6.76, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.92
Price to Book Ratio1.92
Price to Sales Ratio-275.69
Price Cash Flow Ratio-6.76
Price Earnings to Growth Ratio-0.22
Enterprise Value Multiple-14.12
Price Fair Value1.92
Price to Operating Cash Flow Ratio-6.76
Price to Free Cash Flows Ratio-6.26
Price to Tangible Book Ratio2.86
Enterprise Value to Sales8.69
Enterprise Value Over EBITDA-15.96
EV to Operating Cash Flow-8.03
Earnings Yield-4.93%
Free Cash Flow Yield-12.58%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Denali Therapeutics Inc. (DNLI) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -20.324 in 2024.

What is the ticker symbol of Denali Therapeutics Inc. stock?

The ticker symbol of Denali Therapeutics Inc. stock is DNLI.

What is company IPO date?

IPO date of Denali Therapeutics Inc. is 2017-12-08.

What is company current share price?

Current share price is 20.860 USD.

What is stock market cap today?

The market cap of stock today is 2882789420.000.

What is PEG ratio in 2024?

The current -0.218 is -0.218 in 2024.

What is the number of employees in 2024?

In 2024 the company has 445.